{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T21:25:48Z","timestamp":1790717148063,"version":"4.1.0"},"reference-count":34,"publisher":"BMJ","issue":"7","license":[{"start":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T00:00:00Z","timestamp":1721433600000},"content-version":"unspecified","delay-in-days":19,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"NIH\/NCI Cancer Center","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2024,6,25]]},"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Limited data exist for management strategies targeting immunotherapy-related enteritis (irEnteritis). Systemic corticosteroids are commonly used but often are limited by adverse events. Enteric corticosteroids such as budesonide offer an attractive alternative; however, the ileocolonic release of enteric-coated budesonide has limited utility for diffuse enteritis. Open-capsule budesonide (OCB) is a novel therapeutic approach that offers drug delivery throughout the small bowel. We report outcomes in patients treated with OCB for confirmed or suspected irEnteritis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This retrospective cohort included all individuals treated with OCB for irEnteritis at Memorial Sloan Kettering from July 2018 to August 2023. Primary outcomes included clinical response, clinical remission, and corticosteroid-free remission following OCB. Secondary outcomes were OCB-related adverse events and efficacy by gastrointestinal toxicity location.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>19 patients (53% female) with irEnteritis were treated with OCB. All patients presented with diarrhea; 15 (79%) reported anorexia with median 6\u2009kg weight loss. 17 patients (89%) underwent esophagogastroduodenoscopy with biopsies revealing enteritis in all; 8 (42%) had concomitant colitis. 15 (79%) patients were treated previously with systemic corticosteroids: 8 (53%) were corticosteroid-dependent while 7 (47%) demonstrated non-response. 18 patients (95%) achieved clinical response, 15 (79%) attained clinical remission, and 11 (58%) had corticosteroid-free remission. Response to OCB was rapid with improvement noted after a median 4\u2009days. 14 (74%) patients restored their pre-irEnteritis weight by OCB cessation. One mild, self-resolving adverse event was reported.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>OCB is a safe and effective therapy for irEnteritis. OCB avoids systemic immunosuppression and successfully achieves clinical response and remission even in patients previously nonresponsive to systemic corticosteroids. Future studies are needed to optimize indications and duration.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2024-009051","type":"journal-article","created":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T04:32:17Z","timestamp":1721622737000},"page":"e009051","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":9,"title":["Open-capsule budesonide for the treatment of immune-related enteritis from checkpoint inhibitors"],"prefix":"10.1136","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2083-3398","authenticated-orcid":false,"given":"Patrick Tiongco","family":"Magahis","sequence":"first","affiliation":[{"name":"Weill Cornell Medical College, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara","family":"Corso","sequence":"additional","affiliation":[{"name":"Gastroenterology, Hepatology, and Nutrition Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Livingstone","sequence":"additional","affiliation":[{"name":"Gastroenterology, Hepatology, and Nutrition Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Tom","sequence":"additional","affiliation":[{"name":"Gastroenterology, Hepatology, and Nutrition Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amitabh","family":"Srivastava","sequence":"additional","affiliation":[{"name":"Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3367-7961","authenticated-orcid":false,"given":"Michael","family":"Postow","sequence":"additional","affiliation":[{"name":"Weill Cornell Medical College, New York, New York, USA"},{"name":"Melanoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8245-9653","authenticated-orcid":false,"given":"David","family":"Faleck","sequence":"additional","affiliation":[{"name":"Weill Cornell Medical College, New York, New York, USA"},{"name":"Gastroenterology, Hepatology, and Nutrition Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,7,20]]},"reference":[{"key":"2025100304451098000_12.7.e009051.1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.4358"},{"key":"2025100304451098000_12.7.e009051.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.02.011"},{"key":"2025100304451098000_12.7.e009051.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481"},{"key":"2025100304451098000_12.7.e009051.4","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.01547","article-title":"Checkpoint blockade toxicity and immune homeostasis in the gastrointestinal tract","volume":"8","author":"Dougan","year":"2017","journal-title":"Front Immunol"},{"key":"2025100304451098000_12.7.e009051.5","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx225"},{"key":"2025100304451098000_12.7.e009051.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2020.01.033"},{"key":"2025100304451098000_12.7.e009051.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2019.04.002"},{"key":"2025100304451098000_12.7.e009051.8","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1053\/j.gastro.2020.08.063","article-title":"AGA clinical practice update on diagnosis and management of immune checkpoint inhibitor colitis and hepatitis","volume":"160","author":"Dougan","year":"2021","journal-title":"Gastroenterology"},{"key":"2025100304451098000_12.7.e009051.9","doi-asserted-by":"crossref","first-page":"230","DOI":"10.6004\/jnccn.2020.0012","article-title":"NCCN guidelines insights: management of immunotherapy-related toxicities, version 1.2020","volume":"18","author":"Thompson","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"key":"2025100304451098000_12.7.e009051.10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01440"},{"key":"2025100304451098000_12.7.e009051.11","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31629"},{"key":"2025100304451098000_12.7.e009051.12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.79.0006"},{"key":"2025100304451098000_12.7.e009051.13","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ejca.2020.09.022","article-title":"Impact of systemic corticosteroids on survival outcomes in immune checkpoint inhibitor-induced gastroenterocolitis","volume":"142","author":"Thompson","year":"2021","journal-title":"Eur J Cancer"},{"key":"2025100304451098000_12.7.e009051.14","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-018-0346-6","article-title":"Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson","volume":"6","author":"Wang","year":"2018","journal-title":"J Immunother Cancer"},{"key":"2025100304451098000_12.7.e009051.15","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw539"},{"key":"2025100304451098000_12.7.e009051.16","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(94)90131-7"},{"key":"2025100304451098000_12.7.e009051.17","doi-asserted-by":"crossref","unstructured":"Miehlke S , Acosta MB , Bouma G , et al . Oral Budesonide in gastrointestinal and liver disease: a practical guide for the clinician. J Gastroenterol Hepatol 2018. doi:10.1111\/jgh.14151","DOI":"10.1111\/jgh.14151"},{"key":"2025100304451098000_12.7.e009051.18","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-019-0756-0","article-title":"Budesonide treatment for microscopic colitis from immune checkpoint inhibitors","volume":"7","author":"Hughes","year":"2019","journal-title":"J Immunother Cancer"},{"key":"2025100304451098000_12.7.e009051.19","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2017.71"},{"key":"2025100304451098000_12.7.e009051.20","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.cgh.2017.12.044","article-title":"Features of adult autoimmune enteropathy compared with refractory celiac disease","volume":"16","author":"Sharma","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025100304451098000_12.7.e009051.21","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2003.01426.x"},{"key":"2025100304451098000_12.7.e009051.22","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/s41416-020-0882-y","article-title":"Immune checkpoint inhibitor-related colitis assessment and prognosis: can IBD scoring point the way","volume":"123","author":"Cheung","year":"2020","journal-title":"Br J Cancer"},{"key":"2025100304451098000_12.7.e009051.23","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.ejca.2017.07.029","article-title":"Nivolumab-associated nausea and vomiting as an immune adverse event","volume":"84","author":"Shi","year":"2017","journal-title":"Eur J Cancer"},{"key":"2025100304451098000_12.7.e009051.24","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.gie.2017.04.033","article-title":"Acute hemorrhagic Gastritis after Nivolumab treatment","volume":"86","author":"Kobayashi","year":"2017","journal-title":"Gastrointest Endosc"},{"key":"2025100304451098000_12.7.e009051.25","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1093\/annonc\/mdx403","article-title":"Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies","volume":"28","author":"Collins","year":"2017","journal-title":"Ann Oncol"},{"key":"2025100304451098000_12.7.e009051.26","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1080\/00365521.2019.1594356","article-title":"Upper gastrointestinal symptoms and associated endoscopic and histological features in patients receiving immune checkpoint inhibitors","volume":"54","author":"Tang","year":"2019","journal-title":"Scand J Gastroenterol"},{"key":"2025100304451098000_12.7.e009051.27","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/his.13963","article-title":"Immune-related adverse events in the gastrointestinal tract: diagnostic utility of upper gastrointestinal biopsies","volume":"76","author":"Zhang","year":"2020","journal-title":"Histopathology"},{"key":"2025100304451098000_12.7.e009051.28","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6385"},{"key":"2025100304451098000_12.7.e009051.29","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0000000000000165"},{"key":"2025100304451098000_12.7.e009051.30","doi-asserted-by":"crossref","DOI":"10.14309\/crj.0000000000000882","article-title":"Open-capsule Budesonide for the treatment of isolated immune checkpoint inhibitor-induced Enteritis","volume":"9","author":"Hussain","year":"2022","journal-title":"ACG Case Rep J"},{"key":"2025100304451098000_12.7.e009051.31","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000001774"},{"key":"2025100304451098000_12.7.e009051.32","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2014-308363"},{"key":"2025100304451098000_12.7.e009051.33","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000604","article-title":"Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy","volume":"8","author":"Haanen","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2025100304451098000_12.7.e009051.34","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000958","article-title":"Immune checkpoint inhibitor-associated celiac disease","volume":"8","author":"Badran","year":"2020","journal-title":"J Immunother Cancer"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2024-009051","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T11:45:24Z","timestamp":1759491924000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2024-009051"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":34,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,7,20]]},"published-print":{"date-parts":[[2024,7]]}},"alternative-id":["10.1136\/jitc-2024-009051"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2024-009051","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7]]}}}